



# Anti-Diabetic *In-Vivo* Animal Models: A Review

Avinash Bichave<sup>1</sup>, Tejaswi Bandgar<sup>2</sup>, Rina Kadu<sup>3</sup>, Shruti Khopkar<sup>4</sup>, Shrutika Patil<sup>5</sup>

<sup>1</sup>Assistant Professor, <sup>2</sup>Final Year Student, <sup>3</sup>Final Year Student, <sup>4</sup>Final Year Student, <sup>5</sup>Principal Bachelor of Pharmacy,

1TMV's Lokmanya Tilak Institute of Pharmacy, Kharghar, India

**Abstract:** Diabetes mellitus is a chronic metabolic disorder with severe health implications, characterized by persistent hyperglycemia due to insufficient insulin production or impaired insulin action. The aim of this review is to provide a comprehensive overview of in-vivo animal models used in diabetes research, which are essential for understanding the disease mechanisms and developing new therapeutic interventions. This review explores the classification of diabetes, emphasizing the need for appropriate animal models that accurately mimic human diabetes conditions. Key models discussed include Non-Obese Diabetic (NOD) mice for Type 1 diabetes and Zucker Diabetic Fatty (ZDF) rats for Type 2 diabetes, among others.

The review highlights the strengths and limitations of various models, discussing their respective advantages and applications in studying different aspects of diabetes. Additionally, it addresses the critical ethical considerations involved in animal research, focusing on the principles of Replacement, Reduction, and Refinement (3Rs). Advances in genetic manipulation techniques, such as CRISPR/Cas9, and the development of humanized models are also reviewed, showcasing their potential to enhance the relevance and applicability of animal models in diabetes research.

Ultimately, this review aims to guide researchers in selecting suitable animal models for their studies, thereby contributing to the development of effective treatments and interventions for diabetes.

**Keywords:** Diabetes mellitus, *In-vivo* animal models, Type 1 diabetes, Type 2 diabetes  
Keywords: Diabetes mellitus, In-vivo animal models, Type 1 diabetes, Type 2 diabetes.

## I. INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder that poses significant health challenges worldwide, affecting millions of individuals<sup>1</sup>. This condition is characterized by persistent hyperglycemia, which arises from either insufficient insulin production, impaired insulin action, or a combination of both<sup>2</sup>. The chronic elevation of blood glucose levels can lead to severe complications, including cardiovascular diseases, neuropathy, nephropathy, and retinopathy, significantly impacting the quality of life and increasing mortality rates<sup>3</sup>.

**Classification of Diabetes Mellitus:** The classification of diabetes mellitus is broadly categorized into three main types: Type 1 diabetes (T1D), Type 2 diabetes (T2D), and gestational diabetes.

**Type 1 Diabetes (T1D):** Type 1 diabetes is an autoimmune condition where the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. This destruction leads to an absolute deficiency of insulin, necessitating lifelong insulin replacement therapy for those affected. T1D typically manifests during childhood or adolescence but can occur at any age. The exact cause of T1D remains elusive, although it is believed to result from a combination of genetic predisposition and environmental triggers. Researchers focus on understanding the autoimmune mechanisms involved in T1D to develop strategies for prevention and treatment<sup>4</sup>.

**Type 2 Diabetes (T2D):** Type 2 diabetes is characterized by insulin resistance, where the body's cells do not respond effectively to insulin, coupled with a relative deficiency in insulin production. T2D is the most common form of diabetes, accounting for approximately 90-95% of all diabetes cases. This form of diabetes generally develops in adults over the age of 45 but is increasingly being diagnosed in younger populations, including adolescents and children. The rise in T2D cases is closely associated with lifestyle factors such as obesity, physical inactivity, and poor dietary habits. Unlike T1D, T2D has a strong genetic component, but environmental factors play a crucial role in its onset and progression. Effective management of T2D focuses on lifestyle modifications, oral hypoglycemic agents, and, in some cases, insulin therapy<sup>5</sup>.

**Gestational Diabetes:** Gestational diabetes occurs during pregnancy and is typically diagnosed in the second or third trimester. This condition is characterized by glucose intolerance that was not present before pregnancy. Although gestational diabetes usually

resolves after childbirth, it increases the risk of developing T2D later in life for both the mother and the child. Managing gestational diabetes involves monitoring blood glucose levels, dietary modifications, physical activity, and sometimes insulin therapy<sup>6</sup>.

**The Role of Animal Models in Diabetes Research:** Given the complexity and heterogeneity of diabetes, animal models play an indispensable role in advancing our understanding of the disease<sup>7</sup>. *In-vivo* animal models are crucial for investigating the underlying pathophysiological mechanisms, testing new therapeutic interventions, and exploring potential complications associated with diabetes. These models provide a controlled environment where researchers can manipulate various factors to study their effects on diabetes development and progression<sup>8</sup>.

**Importance of *In-vivo* Animal Models:** *In-vivo* animal models offer several advantages in diabetes research. They enable the study of the entire organism's response to genetic, pharmacological, and environmental interventions. Animal models can mimic human diabetes conditions closely, allowing researchers to observe the natural course of the disease, identify biomarkers, and evaluate the efficacy and safety of new treatments. Moreover, these models facilitate the exploration of the interactions between different organ systems affected by diabetes, providing comprehensive insights into the disease's multifaceted nature<sup>9</sup>.

**Selecting Appropriate Animal Models:** Selecting the appropriate animal model is critical for obtaining relevant and translatable findings. An ideal animal model should closely resemble the human condition in terms of pathology, disease progression, and response to treatments. It should also be reproducible, practical in terms of handling and cost, and ethically justifiable. The choice of model often depends on the specific research question, the type of diabetes being studied, and the desired outcomes<sup>10</sup>.

In this review, we will explore the various *In-vivo* animal models used in diabetes research, highlighting their respective advantages, limitations, and applications. By understanding the strengths and weaknesses of each model, researchers can make informed decisions in selecting the most suitable models for their studies, ultimately contributing to the development of effective treatments and interventions for diabetes.

## II. CRITERIA FOR AN IDEAL ANIMAL MODEL

Selecting an appropriate animal model is crucial for diabetes research as it ensures the validity and applicability of the findings to human diabetes. An ideal animal model should exhibit several key characteristics to effectively mimic the human condition and provide meaningful insights.

**Pathophysiological Similarity:** The model should accurately replicate the metabolic and biochemical abnormalities observed in diabetic patients, including hyperglycemia, insulin resistance, beta-cell dysfunction, and diabetic complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease<sup>11</sup>.

**Reproducibility:** The model should consistently produce similar results under the same experimental conditions, allowing different researchers to validate and compare findings across studies. High reproducibility ensures that observed effects are due to the experimental intervention rather than variability in the model itself<sup>12</sup>.

**Ease of Handling and Cost:** Models that are easy to handle and have well-documented husbandry requirements are preferred as they reduce the complexity and cost of conducting experiments. Rodent models, particularly mice and rats, are commonly used due to their small size, short reproductive cycles, and relatively low maintenance costs<sup>13</sup>.

**Ethical Considerations:** Researchers must adhere to strict ethical guidelines and regulations to ensure the humane treatment of animals. This includes minimizing pain and distress, using the minimum number of animals necessary to achieve scientific objectives, and implementing refinement, reduction, and replacement (3Rs) principles wherever possible<sup>14</sup>.

**Genetic Manipulability:** The ability to genetically manipulate animal models is valuable. Genetically modified models, such as knockout and transgenic mice, allow researchers to study the role of specific genes in the development and progression of diabetes<sup>15</sup>.

**Longitudinal Study Capability:** An ideal animal model should allow for long-term studies to observe the progression of diabetes and its complications over time. This capability is important for understanding the chronic nature of the disease and for evaluating the long-term efficacy and safety of potential treatments<sup>16</sup>.

**Translatability to Human Studies:** The ultimate goal of using animal models is to generate findings that are translatable to human diabetes. This requires careful consideration of the physiological and metabolic differences between the model and humans<sup>17</sup>.

## III. TYPES OF ANIMAL MODELS FOR DIABETES

Understanding diabetes requires the use of various animal models that accurately reflect different aspects of the disease. These models can be categorized into spontaneous models, induced models, genetic models, and diet-induced models. Each type of model has its own principles, advantages, disadvantages, and applications, which are crucial for selecting the appropriate model for specific research purposes.

### A. Spontaneous Models

#### 1. Non-Obese Diabetic (NOD) Mice:

The Non-Obese Diabetic (NOD) mouse is a widely utilized model for studying Type 1 diabetes (T1D). These mice develop autoimmune diabetes spontaneously, which closely mimics the pathogenesis of T1D in humans. The principal mechanism involves the immune system's attack on insulin-producing beta cells in the pancreas, leading to their destruction and resulting in hyperglycemia. NOD mice exhibit many immunological features seen in human T1D, including the presence of autoreactive T cells and autoantibodies. This model allows researchers to investigate the genetic and environmental factors contributing to the disease,

providing a platform for studying the interactions between genetic predisposition and environmental triggers. However, the variability in the onset and incidence of diabetes can complicate experimental design and data interpretation. Despite these challenges, NOD mice are invaluable for immunotherapy research and genetic studies, helping to elucidate the mechanisms of autoimmunity and develop strategies to prevent or reverse beta-cell destruction<sup>18</sup>.

## 2. Goto-Kakizaki (GK) Rats:

Goto-Kakizaki (GK) rats are a non-obese model for Type 2 diabetes (T2D), developed through selective breeding of Wistar rats with impaired glucose tolerance. This model mirrors many aspects of human T2D, such as insulin resistance, beta-cell dysfunction, and glucose intolerance, without the confounding factor of obesity. The primary advantage of using GK rats is the ability to study the metabolic aspects of T2D in the absence of obesity, which is often a complicating factor in other models. The genetic predisposition to diabetes in these rats makes them particularly useful for studying hereditary factors. However, the polygenic nature of diabetes in GK rats can complicate the identification of specific genetic contributors to the disease. Researchers use GK rats to explore the pathophysiology of T2D and test pharmacological interventions aimed at improving insulin sensitivity and beta-cell function<sup>19</sup>.

## B. Induced Models

### 1. Streptozotocin (STZ)-induced Diabetes:

Streptozotocin (STZ) is a naturally occurring chemical that selectively destroys insulin-producing beta cells in the pancreas, inducing hyperglycemia and mimicking Type 1 diabetes. Administered via injection, STZ's dosage can be adjusted to induce either partial or complete beta-cell destruction, making it versatile for studying various stages of diabetes. The primary advantage of this model is its ability to reliably produce diabetes in a controlled manner. Researchers can investigate the mechanisms of beta-cell destruction and test insulin replacement therapies and beta-cell regeneration strategies. However, STZ can also cause toxicity to other organs, such as the liver and kidneys, which is a notable limitation. Despite this, the STZ-induced model remains a cornerstone for diabetes research due to its reproducibility and relevance to human T1D<sup>20</sup>.

### 2. Alloxan-induced Diabetes:

Alloxan is another chemical agent used to induce diabetes by selectively destroying beta cells through the generation of reactive oxygen species. This rapid induction of diabetes is beneficial for creating quick models for experimental studies. The principal mechanism involves oxidative stress leading to beta-cell destruction, which mimics the pathogenesis of Type 1 diabetes. The alloxan-induced model is particularly useful for studying the effects of oxidative stress on beta-cell viability and developing antioxidants and other protective agents. However, the variability in diabetes onset and potential nephrotoxicity and other side effects can limit its use. Nevertheless, the alloxan model is valuable for studying both acute and chronic complications of diabetes and for testing new therapeutic approaches.

## C. Genetic Models

### 1. Zucker Diabetic Fatty (ZDF) Rats:

Zucker Diabetic Fatty (ZDF) rats are genetically predisposed to develop obesity and Type 2 diabetes due to a mutation in the leptin receptor gene. These rats exhibit characteristics of metabolic syndrome, including hyperglycemia, hyperlipidemia, and insulin resistance, making them an excellent model for studying the link between obesity and T2D. The primary advantage of ZDF rats is their ability to model the metabolic disturbances associated with obesity-related diabetes. Researchers use this model to study the pathophysiology of insulin resistance and beta-cell dysfunction and to test pharmacological interventions aimed at improving metabolic health. However, the extreme obesity in ZDF rats may limit the applicability of findings to all human T2D patients, as not all individuals with T2D are obese<sup>21</sup>.

### 2. db/db Mice (Leptin Receptor-deficient):

The db/db mouse is another genetic model for Type 2 diabetes, characterized by a mutation in the leptin receptor gene that leads to severe obesity and diabetes. These mice develop insulin resistance, hyperglycemia, and beta-cell dysfunction, closely mirroring human T2D. The principal advantage of this model is its ability to replicate many aspects of human metabolic syndrome and T2D. Researchers use db/db mice to study the mechanisms of insulin resistance and the role of leptin signaling in metabolism, as well as to evaluate the efficacy of glucose-lowering agents and insulin sensitizers. However, similar to the ZDF rat, the extreme obesity in db/db mice may not represent all cases of human T2D, limiting the generalizability of findings<sup>22</sup>.

## D. Diet-induced Models

### 1. High-fat Diet-induced Diabetes:

Feeding animals a high-fat diet (HFD) is a common method to induce insulin resistance and hyperglycemia, mimicking the dietary influences that contribute to Type 2 diabetes in humans. The principal mechanism involves prolonged consumption of high-fat content, leading to metabolic disturbances and the development of insulin resistance. This model closely replicates the gradual onset of T2D, making it useful for studying the disease's progression and testing interventions aimed at preventing or reversing metabolic disturbances. The primary advantage of the high-fat diet model is its relevance to human dietary habits and the study of obesity-

related diabetes. However, the variability in responses to the diet among individual animals can be a challenge, necessitating careful experimental design and interpretation<sup>23</sup>.

## 2. Fructose-fed Models:

Fructose-fed models involve feeding animals a diet high in fructose to induce insulin resistance and hyperglycemia. This model is used to study the effects of high sugar intake on the development of Type 2 diabetes and metabolic syndrome. The principal mechanism involves dietary induction of diabetes through high fructose consumption, leading to metabolic changes such as increased triglycerides, hepatic steatosis, and insulin resistance. The fructose-fed model is beneficial for understanding the role of dietary sugars in metabolic diseases and testing dietary interventions. However, it may not fully capture the complexity of human T2D, and the metabolic changes induced by fructose may differ from those caused by other dietary factors<sup>24</sup>.

**Table 01: Summary of In-Vivo Animal Models for Diabetes**

Model	Principle	Advantages	Disadvantages	Applications
<b>Non-Obese Diabetic (NOD) Mice</b>	Spontaneously develop autoimmune diabetes due to immune system attacking beta cells.	Closely mimics human T1D; useful for immunotherapy research.	Variability in disease onset; limited scope of autoimmunity.	Studying genetic and environmental factors; developing immunotherapies.
<b>Goto-Kakizaki (GK) Rats</b>	Non-obese rats developed through selective breeding for impaired glucose tolerance.	Non-obese model allows study of T2D without obesity; genetic consistency.	Polygenic nature complicates identification of specific genetic factors.	Exploring pathophysiology of T2D; testing pharmacological interventions.
<b>Streptozotocin (STZ)-induced Diabetes</b>	Chemical selectively destroys beta cells, inducing T1D-like hyperglycemia.	Reliable and controllable; versatile for various stages of diabetes.	Potential toxicity to other organs.	Studying beta-cell destruction and regeneration; testing insulin therapies.
<b>Alloxan-induced Diabetes</b>	Chemical induces diabetes by generating reactive oxygen species that destroy beta cells.	Rapid induction; useful for studying oxidative stress effects.	Variability in diabetes onset; potential nephrotoxicity.	Investigating oxidative stress on beta cells; developing protective agents.
<b>Zucker Diabetic Fatty (ZDF) Rats</b>	Genetically predisposed to obesity and T2D due to leptin receptor mutation.	Models metabolic disturbances of obesity-related diabetes.	Extreme obesity limits applicability to all T2D cases.	Studying insulin resistance and beta-cell dysfunction; testing metabolic health interventions.
<b>db/db Mice (Leptin Receptor-deficient)</b>	Mutation in leptin receptor gene leads to severe obesity and diabetes.	Replicates human metabolic syndrome and T2D aspects.	Extreme obesity may not represent all T2D cases.	Exploring insulin resistance and leptin signaling; evaluating glucose-lowering agents.
<b>High-fat Diet-induced Diabetes</b>	Prolonged high-fat diet induces insulin resistance and hyperglycemia.	Relevant to human dietary habits; models gradual T2D onset.	Variability in individual responses to diet.	Studying progression of T2D; testing dietary and pharmacological interventions.
<b>Fructose-fed Models</b>	High fructose diet induces insulin resistance and hyperglycemia.	Useful for studying dietary sugars' impact on metabolic diseases.	May not fully capture complexity of human T2D.	Investigating role of dietary sugars; testing dietary interventions.

## IV. EVALUATION OF ANTI-DIABETIC COMPOUNDS

Evaluating the efficacy and safety of anti-diabetic compounds is a critical aspect of diabetes research, and *In-vivo* animal models play a crucial role in this process. These models allow researchers to test potential therapies in a whole-organism context, providing valuable insights into pharmacodynamics, pharmacokinetics, and potential side effects.

**Pharmacological Testing:** *In-vivo* pharmacological testing involves administering potential anti-diabetic compounds to animal models of diabetes and monitoring their effects on blood glucose levels, insulin sensitivity, and other metabolic parameters. This testing is essential for determining the dose-response relationship and identifying the therapeutic window of new drugs. Animal

models such as streptozotocin (STZ)-induced diabetic mice or Zucker Diabetic Fatty (ZDF) rats are frequently used for these studies. These models enable researchers to evaluate both the acute and chronic effects of the compounds, offering a comprehensive assessment of their therapeutic potential<sup>25</sup>.

**Metabolic Parameters:** Several key metabolic parameters are measured to evaluate the efficacy of anti-diabetic compounds. These include blood glucose levels, glycated hemoglobin (HbA1c), plasma insulin levels, glucose tolerance test (GTT) results, and insulin tolerance test (ITT) results. Regular monitoring of fasting and postprandial blood glucose levels provides a direct measure of the compound's ability to lower glucose levels. HbA1c levels reflect long-term glycemic control and are a crucial indicator of the compound's effectiveness over time. Measuring insulin levels helps determine the compound's impact on insulin secretion and beta-cell function<sup>26</sup>.

**Histopathological Examination:** In addition to metabolic parameters, histopathological examination of tissues such as the pancreas, liver, kidneys, and adipose tissue is performed to assess the structural and cellular effects of anti-diabetic compounds. Evaluating the number and function of beta cells helps determine if the compound preserves or restores beta-cell function. Assessing the liver and kidneys for signs of steatosis, fibrosis, and other pathological changes provides information on potential toxicities and side effects. Analyzing the extent of inflammation in adipose tissue can reveal the compound's impact on insulin resistance and metabolic health<sup>27</sup>.

**Biochemical Markers:** Biochemical markers such as lipid profiles, liver enzymes, and inflammatory cytokines are also measured to assess the broader metabolic effects of anti-diabetic compounds. Changes in triglycerides, cholesterol levels, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels, as well as markers of inflammation like tumor necrosis factor-alpha (TNF- $\alpha$ ) and interleukin-6 (IL-6), provide additional insights into the compound's efficacy and safety.

**Table 02: Common Biochemical Markers Used in Diabetes Research**

Marker	Description	Significance
<b>Triglycerides</b>	Measures levels of triglycerides in blood <sup>28</sup> .	Indicator of lipid metabolism and insulin resistance <sup>28</sup> .
<b>Cholesterol Levels</b>	Assesses total cholesterol, LDL, HDL <sup>29</sup> .	Provides insights into cardiovascular risk factors <sup>29</sup> .
<b>Alanine Aminotransferase (ALT)</b>	Liver enzyme indicating liver health <sup>30</sup> .	High levels can indicate liver damage or fatty liver disease <sup>30</sup> .
<b>Aspartate Aminotransferase (AST)</b>	Another liver enzyme used alongside ALT <sup>31</sup> .	High levels can indicate liver damage <sup>31</sup> .
<b>Tumor Necrosis Factor-alpha (TNF-<math>\alpha</math>)</b>	Inflammatory cytokine <sup>32</sup> .	Marker of inflammation and insulin resistance <sup>32</sup> .
<b>Interleukin-6 (IL-6)</b>	Another inflammatory cytokine <sup>33</sup> .	Marker of systemic inflammation and metabolic syndrome <sup>33</sup> .

**Mechanistic Studies:** Mechanistic studies aim to elucidate the underlying mechanisms by which anti-diabetic compounds exert their effects. These studies often involve examining the expression and activity of key proteins and genes involved in glucose and lipid metabolism, insulin signaling, and inflammatory pathways<sup>34</sup>. Techniques such as Western blotting, quantitative PCR, and immunohistochemistry are commonly used to investigate these mechanisms<sup>35</sup>.

**Comparative Analysis:** Reviewing recent studies and comparing the effectiveness of different compounds across various animal models can provide valuable insights into the strengths and limitations of each model. For example, a compound that effectively lowers blood glucose in STZ-induced diabetic mice may not perform as well in diet-induced obesity models, highlighting the importance of selecting appropriate models for specific research questions<sup>36</sup>.

**Table 03: Key Metabolic Parameters in Evaluating Anti-Diabetic Compounds**

Parameter	Description	Importance
<b>Blood Glucose Levels</b>	Measures fasting and postprandial glucose levels <sup>37</sup> .	Direct measure of compound's glucose-lowering ability <sup>37</sup> .
<b>Glycated Hemoglobin (HbA1c)</b>	Reflects long-term glycemic control <sup>38</sup> .	Indicator of compound's effectiveness over time <sup>38</sup> .
<b>Plasma Insulin Levels</b>	Assesses insulin secretion and beta-cell function <sup>39</sup> .	Determines impact on insulin production. <sup>39</sup>

<b>Glucose Tolerance Test (GTT)</b>	Evaluates body's ability to clear glucose from bloodstream <sup>40</sup> .	Provides insights into glucose metabolism and insulin sensitivity <sup>40</sup> .
<b>Insulin Tolerance Test (ITT)</b>	Measures response to exogenous insulin <sup>41</sup> .	Evaluates insulin sensitivity <sup>41</sup> .

## V. ETHICAL CONSIDERATIONS

Animal research, particularly in the study of diseases like diabetes, necessitates stringent ethical considerations to ensure humane treatment and minimize suffering. Adhering to ethical guidelines and regulations is crucial for the responsible use of animal models in scientific research.

**Animal Welfare:** Ensuring the welfare of animals used in research is paramount. Researchers must follow the principles of the 3Rs: Replacement, Reduction, and Refinement. Replacement refers to the use of alternative methods when possible, such as in vitro studies or computer modeling. Reduction involves using the minimum number of animals necessary to obtain valid results, thereby minimizing the impact on animal populations. Refinement means modifying procedures to minimize pain, distress, and suffering, improving overall animal care and handling practices<sup>42</sup>.

**Regulatory Compliance:** Researchers must comply with local, national, and international regulations governing the use of animals in research. This includes obtaining necessary approvals from institutional animal care and use committees (IACUCs) or equivalent ethical review boards. These committees review research protocols to ensure that they meet ethical standards and that animal use is justified. They also monitor ongoing studies to ensure continued compliance with approved protocols<sup>43</sup>.

**Pain and Distress Minimization:** Efforts should be made to minimize pain and distress in animal models. This includes the use of analgesics and anesthetics during and after invasive procedures. Researchers should be trained in recognizing signs of pain and distress and in implementing appropriate interventions. Humane endpoints should be established, where animals are euthanized if they reach a predetermined level of suffering or illness that cannot be alleviated<sup>44</sup>.

**Housing and Care:** Proper housing and care are essential for the well-being of animal models. This includes providing an appropriate environment that meets the species' physical and behavioral needs. Factors such as housing conditions, social interactions, and enrichment activities should be considered to reduce stress and promote natural behaviors<sup>45</sup>.

## VI. CHALLENGES AND FUTURE DIRECTIONS

Despite the advancements in animal models for diabetes research, several limitations remain. Differences in physiology, metabolism, and disease progression between animals and humans can limit the translatability of findings. For instance, rodent models, while invaluable, may not fully replicate the complexity of human diabetes, particularly concerning long-term complications and the impact of comorbidities.

Recent technological advances offer promising avenues for improving animal models. The use of CRISPR/Cas9 for precise genetic modifications allows for the creation of models that more closely mimic human diabetes. Additionally, humanized mouse models, which incorporate human genes, cells, or tissues, can provide more relevant insights into human disease mechanisms and treatment responses.

Bridging the gap between animal studies and human clinical trials remains a significant challenge. Enhancing the predictive value of animal models involves integrating data from multiple models and employing advanced analytical techniques. Collaborative efforts between basic researchers, clinicians, and regulatory agencies can facilitate the translation of preclinical findings into effective clinical therapies.

Ongoing efforts to refine ethical practices in animal research are crucial. Developing and implementing alternatives to animal testing, such as organ-on-a-chip technology and advanced computer modeling, can reduce reliance on animal models while still providing valuable data for diabetes research.

## VII. CONCLUSION

In vivo animal models are indispensable tools in diabetes research, providing critical insights into disease mechanisms and the development of new therapies. These models allow researchers to study diabetes in a controlled environment, where various factors such as genetics, diet, and chemical exposures can be manipulated to understand their effects on the disease. The ability to observe the progression of diabetes and its complications in real-time offers unparalleled opportunities to investigate the underlying pathophysiological processes.

The selection of appropriate animal models is crucial for obtaining valid and translatable findings. Each model has its unique strengths and limitations, making it suitable for specific types of diabetes research. For instance, Non-Obese Diabetic (NOD) mice are invaluable for studying the autoimmune aspects of Type 1 diabetes (T1D), while Zucker Diabetic Fatty (ZDF) rats and db/db

mice are excellent for exploring the metabolic dysfunctions characteristic of Type 2 diabetes (T2D). Induced models like the Streptozotocin (STZ) and alloxan models provide consistent and reproducible methods for studying beta-cell destruction and diabetes onset, which are essential for developing insulin replacement therapies and other interventions.

Adherence to ethical guidelines is paramount in conducting animal research. Ensuring the humane treatment of animals involves following the principles of Replacement, Reduction, and Refinement (3Rs). Researchers must seek alternatives to animal use whenever possible, minimize the number of animals used to achieve scientific objectives, and refine experimental procedures to reduce pain and distress. Compliance with ethical standards not only upholds the integrity of the research but also ensures the validity and reproducibility of the findings.

Advancements in model development are continually enhancing the relevance and applicability of animal models. Techniques such as CRISPR/Cas9 for precise genetic modifications and the development of humanized mouse models, which incorporate human genes, cells, or tissues, are pushing the boundaries of what can be achieved in diabetes research. These innovations allow for more accurate modeling of human disease conditions and the testing of new therapeutic strategies.

By leveraging the strengths of various animal models and addressing their limitations, researchers can significantly enhance our understanding of diabetes. This multifaceted approach enables the investigation of different aspects of the disease, from genetic and immunological factors to metabolic dysfunctions and environmental influences. Consequently, this comprehensive understanding paves the way for the development of more effective and targeted therapies, ultimately improving therapeutic outcomes for patients with diabetes. The continued progress in this field relies on the judicious selection of models, adherence to ethical practices, and the integration of cutting-edge technologies in research methodologies.

## VIII. LIST OF ABBREVIATIONS

- T1D: Type 1 Diabetes
- T2D: Type 2 Diabetes
- NOD: Non-Obese Diabetic
- GK: Goto-Kakizaki
- STZ: Streptozotocin
- ZDF: Zucker Diabetic Fatty
- HFD: High-fat Diet
- GTT: Glucose Tolerance Test
- ITT: Insulin Tolerance Test
- HbA1c: Glycated Hemoglobin
- ALT: Alanine Aminotransferase
- AST: Aspartate Aminotransferase
- TNF- $\alpha$ : Tumor Necrosis Factor-alpha
- IL-6: Interleukin-6
- 3Rs: Replacement, Reduction, and Refinement
- IACUC: Institutional Animal Care and Use Committee
- CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats

## IX. ACKNOWLEDGMENTS

We would like to acknowledge the Lokmanya Tilak Institute of Pharmacy, Kharghar, navi-Mumbai-410210 for their valuable support for providing the required facilities for this study.

**X. REFERENCES**

- <sup>1</sup> Tiwari, N., Thakur, A. K., Kumar, V., Dey, A., & Kumar, V. (2014). Therapeutic targets for diabetes mellitus: an update. *Clin Pharmacol Biopharm*, 3(1), 1.
- <sup>2</sup> Campos, C. (2012). Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae. *Postgraduate medicine*, 124(6), 90-97.
- <sup>3</sup> Cade W. T. (2008). Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. *Physical therapy*, 88(11), 1322–1335. <https://doi.org/10.2522/ptj.20080008>
- <sup>4</sup> Belle, T. L. V., Coppieters, K., & Herrath, M. G. v. (2011). Type 1 diabetes: etiology, immunology, and therapeutic strategies. *Physiological Reviews*, 91(1), 79-118. <https://doi.org/10.1152/physrev.00003.2010>
- <sup>5</sup> Hurst, C. P., Rakkapao, N., & Hay, K. (2020). Impact of diabetes self-management, diabetes management self-efficacy and diabetes knowledge on glycemic control in people with Type 2 Diabetes (T2D): A multi-center study in Thailand. *PLoS One*, 15(12), e0244692.
- <sup>6</sup> Kampmann, U., Madsen, L. R., Skajaa, G. O., Iversen, D. S., Moeller, N., & Ovesen, P. (2015). Gestational diabetes: a clinical update. *World journal of diabetes*, 6(8), 1065.
- <sup>7</sup> Chatzigeorgiou, A., Halapas, A., Kalafatakis, K., & Kamper, E. (2009). The use of animal models in the study of diabetes mellitus. *In vivo*, 23(2), 245-258.
- <sup>8</sup> Song, W. J., Shah, R., & Hussain, M. A. (2010). The use of animal models to study stem cell therapies for diabetes mellitus. *ILAR journal*, 51(1), 74-81.
- <sup>9</sup> Domínguez-Oliva, A., Hernández-Ávalos, I., Martínez-Burnes, J., Olmos-Hernández, A., Verduzco-Mendoza, A., & Mota-Rojas, D. (2023). The importance of animal models in biomedical research: current insights and applications. *Animals*, 13(7), 1223.
- <sup>10</sup> Kottaisamy, C. P. D., Raj, D. S., Prasanth Kumar, V., & Sankaran, U. (2021). Experimental animal models for diabetes and its related complications-a review. *Laboratory animal research*, 37(1), 23. <https://doi.org/10.1186/s42826-021-00101-4>
- <sup>11</sup> Cefalu, W. T. (2006). Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition. *ILAR journal*, 47(3), 186-198.
- <sup>12</sup> Bolli, G. B., Feo, P. D., Cosmo, S. D., Perriello, G., Ventura, M. M., Benedetti, M. M., ... & Brunetti, P. (1984). A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. *Diabetes*, 33(8), 732-737.
- <sup>13</sup> Schaumleffel, C. (2023). Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia. *Patient Preference and Adherence*, 17, 2141–2144. <https://doi.org/10.2147/PPA.S325865>
- <sup>14</sup> Hau, J., Schapiro, S. J., & Van Hoosier Jr, G. L. (2004). *Handbook of laboratory animal science: Animal Models*, Volume III. CRC press.
- <sup>15</sup> Haque, S. T., Saha, S. K., Haque, M. E., & Biswas, N. (2021). Nanotechnology-based therapeutic applications: in vitro and in vivo clinical studies for diabetic wound healing. *Biomaterials science*, 9(23), 7705-7747.
- <sup>16</sup> Kumar, S., & Zhuo, L. (2010). Longitudinal in vivo imaging of retinal gliosis in a diabetic mouse model. *Experimental eye research*, 91(4), 530-536.
- <sup>17</sup> Yang, J. F., Gong, X., Bakh, N. A., Carr, K., Phillips, N. F., Ismail-Beigi, F., ... & Strano, M. S. (2020). Connecting rodent and human pharmacokinetic models for the design and translation of glucose-responsive insulin. *Diabetes*, 69(8), 1815-1826.
- <sup>18</sup> Kachapati, K., Adams, D., Bednar, K., & Ridgway, W. M. (2012). The non-obese diabetic (NOD) mouse as a model of human type 1 diabetes. *Animal models in diabetes research*, 3-16.
- <sup>19</sup> Jeppesen, P. B., Gregersen, S., Alstrup, K. K., & Hermansen, K. (2002). Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats. *Phytomedicine*, 9(1), 9-14.
- <sup>20</sup> Furman, B. L. (2021). Streptozotocin-induced diabetic models in mice and rats. *Current protocols*, 1(4), e78.
- <sup>21</sup> Shiota, M., & Printz, R. L. (2012). Diabetes in Zucker diabetic fatty rat. *Animal Models in Diabetes Research*, 103-123.
- <sup>22</sup> Rószter, T., Józsa, T., Kiss-Tóth, É. D., De Clerck, N., & Balogh, L. (2014). Leptin receptor deficient diabetic (db/db) mice are compromised in postnatal bone regeneration. *Cell and tissue research*, 356, 195-206.
- <sup>23</sup> Ikemoto, S., Takahashi, M., Tsunoda, N., Maruyama, K., Itakura, H., & Ezaki, O. (1996). High-fat diet-induced hyperglycemia and obesity in mice: differential effects of dietary oils. *Metabolism*, 45(12), 1539-1546.
- <sup>24</sup> Silva-Reis, R., Faustino-Rocha, A. I., Silva, J., Valada, A., Azevedo, T., Anjos, L., ... & Oliveira, P. A. (2023). Studying and Analyzing Humane Endpoints in the Fructose-Fed and Streptozotocin-Injected Rat Model of Diabetes. *Animals*, 13(8), 1397.
- <sup>25</sup> Kumar, S., Singh, R., Vasudeva, N., & Sharma, S. (2012). Acute and chronic animal models for the evaluation of anti-diabetic agents. *Cardiovascular diabetology*, 11, 1-13.
- <sup>26</sup> Hu, X. F., Zhang, Q., Zhang, P. P., Sun, L. J., Liang, J. C., Morris-Natschke, S. L., ... & Lee, K. H. (2018). Evaluation of in vitro/in vivo anti-diabetic effects and identification of compounds from *Physalis alkekengi*. *Fitoterapia*, 127, 129-137.
- <sup>27</sup> Mansour, H. M., Zeitoun, A. A., Abd-Rabou, H. S., El Enshasy, H. A., Dailin, D. J., Zeitoun, M. A., & El-Sohaimy, S. A. (2023). Antioxidant and anti-diabetic properties of olive (*Olea europaea*) leaf extracts: In vitro and in vivo evaluation. *Antioxidants*, 12(6), 1275.
- <sup>28</sup> Unger, G., Benozzi, S. F., Perruzza, F., & Pennacchiotti, G. L. (2014). Triglycerides and glucose index: a useful indicator of insulin resistance. *Endocrinología y Nutrición (English Edition)*, 61(10), 533-540.
- <sup>29</sup> Amalan, V., Vijayakumar, N., Indumathi, D., & Ramakrishnan, A. (2016). Antidiabetic and antihyperlipidemic activity of p-coumaric acid in diabetic rats, role of pancreatic GLUT 2: In vivo approach. *Biomedicine & Pharmacotherapy*, 84, 230-236.
- <sup>30</sup> Fracanzani, A. L., Valenti, L., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E., ... & Fargion, S. (2008). Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. *Hepatology*, 48(3), 792-798.
- <sup>31</sup> Bishayee, A., Darvesh, A. S., Politis, T., & McGory, R. (2010). Resveratrol and liver disease: from bench to bedside and community. *Liver international*, 30(8), 1103-1114.

- <sup>32</sup> Swaroop, J. J., Rajarajeswari, D., & Naidu, J. N. (2012). Association of TNF- $\alpha$  with insulin resistance in type 2 diabetes mellitus. *Indian Journal of Medical Research*, 135(1), 127-130.
- <sup>33</sup> Jagannatha, S. B. (2014). Study of Serum High Sensitivity C-Reactive Protein, Ferritin, Insulin, C-Peptide and Glycated Hemoglobin in Patients with Type 2 Diabetes Mellitus (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)).
- <sup>34</sup> Hotamisliligil, G. S. (2003). Inflammatory pathways and insulin action. *International Journal of Obesity*, 27(3), S53-S55.
- <sup>35</sup> Che, H., Li, H., Li, Y., Wang, Y. Q., Yang, Z. Y., Wang, R. L., & Wang, L. H. (2020). Melatonin exerts neuroprotective effects by inhibiting neuronal pyroptosis and autophagy in STZ-induced diabetic mice. *The FASEB Journal*, 34(10), 14042-14054.
- <sup>36</sup> Preguiça, I., Alves, A., Nunes, S., Gomes, P., Fernandes, R., Viana, S. D., & Reis, F. (2020). Diet-induced rodent models of diabetic peripheral neuropathy, retinopathy and nephropathy. *Nutrients*, 12(1), 250.
- <sup>37</sup> Oh, M. R., Park, S. H., Kim, S. Y., Back, H. I., Kim, M. G., Jeon, J. Y., ... & Chae, S. W. (2014). Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. *BMC complementary and alternative medicine*, 14, 1-7.
- <sup>38</sup> Yazdanpanah, S., Rabiee, M., Tahriri, M., Abdolrahim, M., Rajab, A., Jazayeri, H. E., & Tayebi, L. (2017). Evaluation of glycated albumin (GA) and GA/HbA1c ratio for diagnosis of diabetes and glycemic control: A comprehensive review. *Critical reviews in clinical laboratory sciences*, 54(4), 219-232.
- <sup>39</sup> Park, S. Y., Gautier, J. F., & Chon, S. (2021). Assessment of insulin secretion and insulin resistance in human. *Diabetes & metabolism journal*, 45(5), 641.
- <sup>40</sup> Andrikopoulos, S., Blair, A. R., Deluca, N., Fam, B. C., & Proietto, J. (2008). Evaluating the glucose tolerance test in mice. *American Journal of Physiology-Endocrinology and Metabolism*, 295(6), E1323-E1332.
- <sup>41</sup> Dorkhan, M., Tripathy, D., Malm, G., Asgharian, H., Tuomi, T., & Groop, L. (2008). Independent measures of insulin secretion and insulin sensitivity during the same test: the glucagon-insulin tolerance test. *Journal of internal medicine*, 264(1), 62-71.
- <sup>42</sup> Stokes, W. S., & Marsman, D. S. (2014). Animal welfare considerations in biomedical research and testing. In *Laboratory Animal Welfare* (pp. 115-140). Academic press.
- <sup>43</sup> Yaşmut, O., & Adaş, M. (2022). Evaluation of Compliance to Diabetes Treatment, Care Standards in Diabetes Treatment and Follow-up and Awareness of Patients. *European Archives of Medical Research*, 38(3).
- <sup>44</sup> Arifin, B., Probandari, A., Purba, A. K. R., Perwitasari, D. A., Schuiling-Veninga, C. C., Atthobari, J., ... & Postma, M. J. (2020). 'Diabetes is a gift from god'a qualitative study coping with diabetes distress by Indonesian outpatients. *Quality of Life Research*, 29(1), 109-125.
- <sup>45</sup> Chen, Y. S., Weng, S. J., Chang, S. H., Li, R. Y., Shane, G. T., Hsu, J. P., ... & Lee, M. J. (2021). Evaluating the antidiabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse models. *Plos one*, 16(8), e0255405.